Published in:
01-07-2016 | Breast
Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging
Published in: European Radiology | Issue 7/2016
Login to get accessAbstract
Objective
To evaluate the performance of 18F-fluorodeoxyglucose (FDG) positron emission tomography magnetic resonance imaging (PET/MR) for preoperative breast cancer staging.
Methods
Preoperative PET/MR exams of 58 consecutive women with breast cancer were retrospectively reviewed. Histology and mean follow-up of 26 months served as gold standard. Four experienced readers evaluated primary lesions, lymph nodes and distant metastases with contrast-enhanced MRI, qualitative/quantitative PET, and combined PET/MR. ROC curves were calculated for all modalities and their combinations.
Results
The study included 101 breast lesions (83 malignant, 18 benign) and 198 lymph node groups, (34 malignant, 164 benign). Two patients had distant metastases. Areas under the curve (AUC) for breast cancer were 0.9558, 0.8347 and 0.8855 with MRI, and with qualitative and quantitative PET/MR, respectively (p = 0.066). Sensitivity for primary cancers with MRI and quantitative PET/MR was 100 % and 77 % (p = 0.004), and for lymph nodes 88 % and 79 % (p = 0.25), respectively. Specificity for MRI and PET/MR for primary cancers was 67 % and 100 % (p = 0.03) and for lymph nodes 98 % and 100 % (p = 0.25).
Conclusions
In breast cancer patients, MRI alone has the highest sensitivity for primary tumours. For nodal metastases, both MRI and PET/MR are highly specific.
Key points
• MRI alone and PET/MR have a similar overall diagnostic performance.
• MRI alone has a higher sensitivity than PET/MR for local tumour assessment.
• Both MRI and PET/MR have a limited sensitivity for nodal metastases.
• Positive lymph nodes on MRI or PET/MR do not require presurgical biopsy.